Hepatic erythropoietin response in cirrhosis. A contemporary review

References

• Jelkmann W. Regulation of erythropoietin production. J Physiol (Lond) 2011;589:1251–8.
   Google Scholar
• Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003;33:891–6.
   PubMed Web of Science ®Google Scholar
• Lonnberg M, Garle M, Lonnberg L, Birgegard G. Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis. J Pharm Biomed Anal 2013;812:187–92.
   Web of Science ®Google Scholar
• Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int 2009;75:682–8.
   PubMed Web of Science ®Google Scholar
• Yang YY, Lin HC, Lee WC, Huang YT, Hou MC, Lee FY, Chang FY, Lee SD. Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. J Gastroenterol Hepatol 2003;18:1156–61.
   PubMed Web of Science ®Google Scholar
• Figueiredo A, Romero-Bermejo F, Perdigoto R, Marcelino P. The end-organ impairment in liver cirrhosis: appointments for critical care. Crit Care Res Pract 2012;2012:539412.
   PubMedGoogle Scholar
• Elliott S, Sinclair AM. The effect of erythropoietin on normal and neoplastic cells. Biologics 2012;6:163–89.
   PubMedGoogle Scholar
• Kochling J, Curtin PT, Madan A. Regulation of human erythropoietin gene induction by upstream flanking sequences in transgenic mice. Br J Haematol 1998;103:960–8.
   PubMed Web of Science ®Google Scholar
• Koury MJ, Koury ST, Bondurant MC, Graber SE. Correlation of the molecular and anatomical aspects of renal erythropoietin production. Contrib Nephrol 1989;76:24–9.
   PubMedGoogle Scholar
• Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 1989;74:645–51.
   PubMed Web of Science ®Google Scholar
• Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int 2008;2:416–28.
   PubMed Web of Science ®Google Scholar
• Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38 Suppl 1:S69–89.
   Google Scholar
• Schrier RW. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–7.
   PubMed Web of Science ®Google Scholar
• Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008;28:26–42.
   PubMed Web of Science ®Google Scholar
• Pagel H, Jelkmann W, Weiss C. O2-supply to the kidneys and the production of erythropoietin. Respir Physiol 1989;77:111–17.
   PubMedGoogle Scholar
• Nouh MA, H, Hossan M, Halim A Sherbiny W. Ezzat R, Siddik. Study of plasma erythropoietin hormone level in patients with liver cirrhosis. Research 2015;3:78–83.
   Google Scholar
• Li XJ, Zhang GX, Sun N, Sun Y, Yang LZ, Du YJ. Protective effects of erythropoietin on endotoxin-related organ injury in rats. J Huazhong Univ Sci Technol Med Sci 2013;33:680–6.
   PubMed Web of Science ®Google Scholar
• Radovic M, Jelkmann W, Djukanovic L, Ostric V. Serum erythropoietin and interleukin-6 levels in hemodialysis patients with hepatitis virus infection. J Interferon Cytokine Res 1999;19:369–73.
   PubMed Web of Science ®Google Scholar
• Brown S, Caro J, Erslev AJ, Murray TG. Spontaneous increase in erythropoietin and hematocrit value associated with transient liver enzyme abnormalities in an anephric patient undergoing hemodialysis. Am J Med 1980;68:280–4.
   PubMed Web of Science ®Google Scholar
• Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004;22:63–9.
   PubMed Web of Science ®Google Scholar
• Peng HS, Xu XH, Zhang R, He XY, Wang XX, Wang WH, Xu TY, Xiao XR. Multiple low doses of erythropoietin delay the proliferation of hepatocytes but promote liver function in a rat model of subtotal hepatectomy. Surg Today 2014;44:1109–15.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang Y, He T, Liu Y, Zhou Y, Chen Y, Xu C. Expression profiles uncover the relationship between erythropoietin and cell proliferation in rat hepatocytes after a partial hepatectomy. Cell Mol Biol Lett 2014;19:331–46.
   PubMed Web of Science ®Google Scholar
• Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006;69:1806–13.
   PubMed Web of Science ®Google Scholar
• Klemm K, Eipel C, Cantre D, Abshagen K, Menger MD, Vollmar B. Multiple doses of erythropoietin impair liver regeneration by increasing TNF-alpha, the Bax to Bcl-xL ratio and apoptotic cell death. PLoS One 2008;3:e3924.
   Google Scholar
• Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999–1007.
   PubMed Web of Science ®Google Scholar
• Schmeding M, Hunold G, Ariyakhagorn V, Rademacher S, Boas-Knoop S, Lippert S, Neuhaus P, Neumann UP. Erythropoietin reduces ischemia-reperfusion injury after liver transplantation in rats. Transpl Int 2009;22:738–46.
   PubMed Web of Science ®Google Scholar
• Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044–9.
   PubMed Web of Science ®Google Scholar
• Lund A, Lundby C, Olsen NV. High-dose erythropoietin for tissue protection. Eur J Clin Invest 2014;44:1230–8.
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014;46:678–84.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 2007;30:15–30.
   PubMed Web of Science ®Google Scholar
• Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991;39:259–65.
   PubMed Web of Science ®Google Scholar
• Resch BE, Gaspar R, Sonkodi S, Falkay G. Vasoactive effects of erythropoietin on human placental blood vessels in vitro. Am J Obstet Gynecol 2003;188:993–6.
   PubMed Web of Science ®Google Scholar
• Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009;4:470–80.
   PubMed Web of Science ®Google Scholar
• Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, Bode-Boger SM. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 2005;16:892–8.
   PubMed Web of Science ®Google Scholar
• Balcioglu A, Watkins CJ, Maher TJ. Use of a hemoglobin-trapping approach in the determination of nitric oxide in in vitro and in vivo systems. Neurochem Res 1998;23:815–20.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Redhead DN, Hayes PC, Webb DJ, Jalan R. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003;9:32–9.
   PubMed Web of Science ®Google Scholar
• Gerbes AL, Moller S, Gulberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735–9.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Tyce GM, Miller VM, Edwards BS, Rorie DK. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999;30:401–7.
   PubMed Web of Science ®Google Scholar
• King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989;256:F1051–8.
   PubMed Web of Science ®Google Scholar
• Moller S, Gulberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995;23:135–44.
   PubMed Web of Science ®Google Scholar
• Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 1992;20 Suppl 12:S25–8.
   Google Scholar
• Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996;50:1255–61.
   PubMed Web of Science ®Google Scholar
• Ueno T, Nakamura T, Torimura T, Sata M. Angiogenic cell therapy for hepatic fibrosis. Med Mol Morphol 2006;39:16–21.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang F, Lu Y, Zheng S. Update on implications and mechanisms of angiogenesis in liver fibrosis. Hepatology Res 2015;45:162–78.
   PubMed Web of Science ®Google Scholar
• Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326–33.
   PubMed Web of Science ®Google Scholar
• Conchillo M, Prieto J, Quiroga J. [Insulin-like growth factor I (IGF-I) and liver cirrhosis]. Rev Esp Enferm Dig 2007;99:156–64.
   PubMed Web of Science ®Google Scholar
• Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004;20:437–43.
   PubMed Web of Science ®Google Scholar
• Kessler SM, Barghash A, Laggai S, Helms V, Kiemer AK. Hepatic hepcidin expression is decreased in cirrhosis and HCC. Int J Mol Sci 2014;15:5762–73.
   PubMed Web of Science ®Google Scholar
• Yilmaz B, Basar O, Altinbas A, Ekiz F, Aktas B, Ozturk G, Ginis Z, Coban S, Ucar E, Erarslan E, Coskun Y, Yuksel I, Tuna Y, Yuksel O. The utility of thrombopoietin in predicting liver fibrosis in chronic hepatitis B. Int J Clin Exp Med 2014;7:1430–4.
   PubMed Web of Science ®Google Scholar
• Muta K, Krantz SB, Bondurant MC, Wickrema A. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1994;94:34–43.
   PubMed Web of Science ®Google Scholar
• Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006;281:2024–32.
   PubMed Web of Science ®Google Scholar
• Jensen JD, Jensen LW, Madsen JK, Poulsen L. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 1995;54:111–16.
   PubMed Web of Science ®Google Scholar
• Gabius HJ. Biological information transfer beyond the genetic code: the sugar code. Naturwissenschaften 2000;87:108–21.
   PubMed Web of Science ®Google Scholar